Download PDF
Horm Metab Res 2019; 51(05): 315-325
DOI: 10.1055/a-0893-3122
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

The Cycle Characteristics and Outcomes of Infertile Nonclassic 21-Hydroxylase Deficiency Patients Undergoing Ovarian Stimulation for In Vitro Fertilization

Shutian Jiang
1   Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
,
Yanping Kuang
1   Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
› Author Affiliations
Further Information

Publication History

received 25 October 2018

accepted 02 April 2019

Publication Date:
09 May 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Background The objective of the work was to investigate the cycle characteristics and outcomes of infertile women with nonclassic 21-hydroxylase deficiency (21-OHD) undergoing in vitro fertilization (IVF).

Methods Twenty-five infertile nonclassic 21-OHD patients were retrospectively observed. From cycle day 3, patients were given human menopausal gonadotropin (HMG) 150 IU/d or 225 IU/d daily. Dexamethasone was administered orally at 0.75 mg/d. Ovulation was co-triggered by human chorionic gonadotropin (hCG) and triptorelin. Binary logistic regression was performed to quantify the effect of IVF parameters on embryo transfer cycle outcomes. The receiver operating characteristic (ROC) curve was used to determine cutoff points of the selected confounders for predicting pregnant probabilities.

Results In controlled ovarian hyperstimulation (COH) cycles, there was a trend that the viable embryos group consisted of more polycystic ovary (PCO) patients. In embryo transfer (ET) cycles, differences were detected in the usage rate of dexamethasone and the minimum progesterone (P4) and total testosterone (TT) values between the non-pregnant group and the biochemical pregnant group. Binary logistic regression analysis confirmed that decreasing minimum P4 and body mass index (BMI) value was respectively correlated with increasing pregnancy probability. ROC analysis proved that the cutoff values for minimum P4 and BMI were 0.45 ng/ml and 23.36 kg/m2.

Conclusion In COH cycles, the ultrasonographic appearance of ovary helps to predict the number of viable embryos. In ET cycles, dexamethasone obviously improves the pregnancy rate. If the minimum P4 value before endometrial transformation cannot be kept below 0.45 ng/ml, we may consider cycle cancellation. Moreover, it is suggested that BMI of nonclassic 21-OHD women is regulated below 23.36 kg/m2.

Key words

congenital adrenal hyperplasia - 21-hydroxylase deficiency - IVF - ovarian stimulation

Supplementary Material

    Supplementary Material for this article is available online at http://www.thieme-connect.de/products
  • Supplementary Material
 

  • References

  • 1 El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet (London, England) 2017; 390: 2194-2210
    CrossrefPubMedGoogle Scholar
  • 2 Speiser PW, White PC. Congenital adrenal hyperplasia. N Eng. J Med 2003; 349: 776-788
    PubMedGoogle Scholar
  • 3 Speiser PW, Dupont B, Rubinstein P. et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Human. Gen 1985; 37: 650-667
    PubMedGoogle Scholar
  • 4 Falhammar H, Nordenstrom A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Clinical presentation, diagnosis, treatment, and outcome. Endocrine 2015; 50: 32-50
    CrossrefPubMedGoogle Scholar
  • 5 New MI. Extensive clinical experience: Nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4205-4214
    CrossrefPubMedGoogle Scholar
  • 6 Child DF, Bu'lock DE, Anderson DC. Adrenal steroidogenesis in hirsute women. Clin Endocrinol 1980; 12: 595-601
    CrossrefPubMedGoogle Scholar
  • 7 Gibson M, Lackritz R, Schiff I. et al. Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertil Steril 1980; 33: 43-48
    CrossrefPubMedGoogle Scholar
  • 8 Lobo RA, Goebelsmann U. Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. Am J Obstetr Gynecol 1980; 138: 720-726
    CrossrefPubMedGoogle Scholar
  • 9 Bidet M, Bellanne-Chantelot C, Galand-Portier MB. et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95: 1182-1190
    CrossrefPubMedGoogle Scholar
  • 10 Han TS, Walker BR, Arlt W. et al. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol 2014; 10: 115-124
    CrossrefPubMedGoogle Scholar
  • 11 Turcu AF, Auchus RJ. Adrenal steroidogenesis and congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2015; 44: 275-296
    CrossrefPubMedGoogle Scholar
  • 12 Moran C, Azziz R, Weintrob N. et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 3451-3456
    CrossrefPubMedGoogle Scholar
  • 13 Falhammar H, Frisen L, Norrby C. et al. Reduced frequency of biological and increased frequency of adopted children in males with 21-hydroxylase deficiency: A swedish population-based national cohort study. J Clin Endocrinol Metab 2017; 102: 4191-4199
    CrossrefPubMedGoogle Scholar
  • 14 Arlt W, Willis DS, Wild SH. et al. Health status of adults with congenital adrenal hyperplasia: A cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95: 5110-5121
    CrossrefPubMedGoogle Scholar
  • 15 Finkielstain GP, Kim MS, Sinaii N. et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97: 4429-4438
    CrossrefPubMedGoogle Scholar
  • 16 Falhammar H, Frisen L, Hirschberg AL. et al. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: A swedish population-based national cohort study. J Clin Endocrinol Metab 2015; 100: 3520-3528
    CrossrefPubMedGoogle Scholar
  • 17 Feldman S, Billaud L, Thalabard JC. et al. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 74: 635-639
    PubMedGoogle Scholar
  • 18 Birnbaum MD, Rose LI. Late onset adrenocortical hydroxylase deficiencies associated with menstrual dysfunction. Obstetr Gynecol 1984; 63: 445-451
    PubMedGoogle Scholar
  • 19 Trakakis E, Dracopoulou-Vabouli M, Dacou-Voutetakis C. et al. Infertility reversed by glucocorticoids and full-term pregnancy in a couple with previously undiagnosed nonclassic congenital adrenal hyperplasia. Fertil Steril 2011; 96: 1048-1050
    CrossrefPubMedGoogle Scholar
  • 20 Cuhaci N, Aydin C, Yesilyurt A et al. Nonclassical congenital adrenal hyperplasia and pregnancy. Case Rep Endocrinol 2015; 296924:
    PubMed
  • 21 Falhammar H, Thoren M, Hagenfeldt K. A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation. J Endocrinol Invest 2008; 31: 176-180
    CrossrefPubMedGoogle Scholar
  • 22 Nussbaum AR, Sanders RC, Hartman DS. et al. Neonatal ovarian cysts: Sonographic-pathologic correlation. Radiology 1988; 168: 817-821
    CrossrefPubMedGoogle Scholar
  • 23 Wang N, Zhang X, Xiang YB. et al. Associations of adult height and its components with mortality: A report from cohort studies of 135 000 Chinese women and men. Int J Epidemiol 2011; 40: 1715-1726
    CrossrefPubMedGoogle Scholar
  • 24 Cameron FJ, Kaymakci B, Byrt EA. et al. Bone mineral density and body composition in congenital adrenal hyperplasia. The J Clin Endocrinol Metab 1995; 80: 2238-2243
    PubMedGoogle Scholar
  • 25 Falhammar H, Filipsson H, Holmdahl G. et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 110-116
    CrossrefPubMedGoogle Scholar
  • 26 Wilcox AJ, Weinberg CR, O'Connor JF. et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189-194
    CrossrefPubMedGoogle Scholar
  • 27 Zinaman MJ, Clegg ED, Brown CC. et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65: 503-509
    CrossrefPubMedGoogle Scholar
  • 28 Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: Current concepts. J Clin Endocrinol Metab 1994; 78: 810-815
    PubMedGoogle Scholar
  • 29 Dewailly D, Vantyghem-Haudiquet MC, Sainsard C. et al. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J Clin Endocrinol Metab 1986; 63: 418-423
    CrossrefPubMedGoogle Scholar
  • 30 Errazuriz VJ, Carrasco A, Diaz RE. et al. [Association between antral follicle count and age in fertile women]. Revista Medica Chile 2017; 145: 741-746
    PubMedGoogle Scholar
  • 31 Chang MY, Chiang CH, Chiu TH. et al. The antral follicle count predicts the outcome of pregnancy in a controlled ovarian hyperstimulation/intrauterine insemination program. J Assist Reprod Genetics 1998; 15: 12-17
    CrossrefPubMedGoogle Scholar
  • 32 Borini A, Dal Prato L. Tailoring FSH and LH administration to individual patients. Reprod Biomed Online 2005; 11: 283-293
    CrossrefPubMedGoogle Scholar
  • 33 Segal S, Shifren JL, Isaacson KB. et al. Effect of a baseline ovarian cyst on the outcome of in vitro fertilization-embryo transfer. Fertil Steril 1999; 71: 274-277
    CrossrefPubMedGoogle Scholar
  • 34 Keltz MD, Jones EE, Duleba AJ. et al. Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome. Fertil Steril 1995; 64: 568-572
    CrossrefPubMedGoogle Scholar
  • 35 Thatcher SS, Jones E, DeCherney AH. Ovarian cysts decrease the success of controlled ovarian stimulation and in vitro fertilization. Fertil Steril 1989; 52: 812-816
    CrossrefPubMedGoogle Scholar
  • 36 Karande VC, Scott RT, Jones GS. et al. Non-functional ovarian cysts do not affect ipsilateral or contralateral ovarian performance during in-vitro fertilization. Human Reprod (Oxford, England) 1990; 5: 431-433
    CrossrefPubMedGoogle Scholar
  • 37 Sampaio M, Serra V, Miro F. et al. Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration. Human Reprod (Oxford, England) 1991; 6: 194-197
    CrossrefPubMedGoogle Scholar
  • 38 Fiszbajn GE, Lipowicz RG, Elberger L. et al. Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction. J Assist Reprod GVenetics 2000; 17: 260-263
    PubMedGoogle Scholar
  • 39 Kuang Y, Hong Q, Chen Q. et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril 2014; 101: 105-111
    CrossrefPubMedGoogle Scholar
  • 40 Kuang Y, Chen Q, Fu Y. et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 2015; 104: 62-70 e63
    CrossrefPubMedGoogle Scholar
  • 41 Gleicher N, Kim A, Weghofer A. et al. Hypoandrogenism in association with diminished functional ovarian reserve. Human Reprod (Oxford, England) 2013; 28: 1084-1091
    CrossrefPubMedGoogle Scholar
  • 42 Gaddas M, Chaouache N, Ajina M. et al. [Does hyperandrogenic statute in the polycystic ovary syndrome constitute an obstacle to the success of in vitro fertilization?]. J Gynecol Obstetr Biol Reprod 2016; 45: 1091-1098
    PubMedGoogle Scholar
  • 43 Sanchez LA, Moran C, Reyna R. et al. Adrenal progestogen and androgen production in 21-hydroxylase-deficient nonclassic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation. Fertil Steril 2002; 77: 750-753
    CrossrefPubMedGoogle Scholar
  • 44 Livadas S, Dracopoulou M, Dastamani A. et al. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin Endocrinol 2015; 82: 543-549
    CrossrefPubMedGoogle Scholar
  • 45 Forest MG, David M, Morel Y. Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 1993; 45: 75-82
    CrossrefPubMedGoogle Scholar
  • 46 Silverberg KM, Burns WN, Olive DL. et al. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J Clin Endocrinol Metab 1991; 73: 797-803
    CrossrefPubMedGoogle Scholar
  • 47 Check JH. Predictive value of serum progesterone levels for pregnancy outcome?. Fertil Steril 1994; 62: 1090-1091
    CrossrefPubMedGoogle Scholar
  • 48 Ubaldi F, Albano C, Peukert M. et al. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. Human Reprod (Oxford, England) 1996; 11: 1405-1407
    CrossrefPubMedGoogle Scholar
  • 49 Purewal S, Chapman SCE, van den Akker OBA. A systematic review and meta-analysis of lifestyle and body mass index predictors of successful assisted reproductive technologies. J Psychosom Obstet Gynaecol 2019; 40: 2-18
    CrossrefPubMedGoogle Scholar